moxetumomab pasudotox

Ligand id: 7675

Name: moxetumomab pasudotox

No information available.
Summary of Clinical Use
Moxetumomab pasudotox was assessed as a potential treatment for B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and hairy cell leukemia [3]. Click here to view ClinicalTrials.gov's listing of moxetumomab pasudotox trials. FDA approval for hairy cell leukemia was granted in 2018. In the EU, the antibody has had EMA orphan designation for the treatment of B-lymphoblastic leukaemia / lymphoma since 2013.
Mechanism Of Action and Pharmacodynamic Effects
The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells.This targets the toxin moiety, PE38, directly to tumor cells. Internalized PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2) [7].
External links